MedTrace Logo

Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

NCT03966118 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2019-06-03

No results posted yet for this study

Summary

Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma following first-line therapy with platinum and fluoropyrimidine doublet with or without anthracycline, docetaxel or trastuzumab

Conditions

  • Gastroesophageal Junction Adenocarcinoma
  • Adenocarcinoma of the Stomach

Interventions

DRUG

Avelumab

Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle

DRUG

Ramucirumab

Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle

DRUG

Paclitaxel

Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle

Sponsors & Collaborators

  • P. C. Thuss-Patience

    lead OTHER

Principal Investigators

  • Peter Thuss-Patience, MD · Charité-University Medicine (Berlin, Germany)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-09-30
Completion
2023-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03966118 on ClinicalTrials.gov